The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Bio-Gene Technology’s (BGT) insecticides could soon be used in mosquito control across North, Central and South America
  • The agtech developer has partnered with Clarke Mosquito Control to further develop formulations of Bio-Gene’s Flavocide and Qcide technologies
  • The partnership follows Clarke’s successful internal testing of the technologies on three different types of mosquitoes
  • Company shares are trading flat for 19.5 cents each

Bio-Gene Technology’s (BGT) insecticides could soon be used in mosquito control across North, Central and South America.

The agtech developer has today announced a partnership with Clarke Mosquito Control to further develop its Flavocide and Qcide technologies.

In August 2019, Bio-Gene signed a Material Transfer Agreement (MTA) with Clarke which allowed Clarke to undertake internal testing of the technologies on Anopheles, Aedes and Culex mosquito species.

Following successful results from the internal testing, Clarke and Bio-Gene inked the agreement which will see them further develop the formulations of Flavocide and Qcide.

Bio-Gene CEO and Managing Director Richard Jagger said the partnership represents a significant milestone for the company.

“This agreement with Clarke has the opportunity to expand into other markets and is very valuable for our discussions with other stakeholders including, for example, NGOs and philanthropists to further develop commercialisation opportunities in the public health space,” he commented.

At present Bio-Gene is in discussions with other companies, seven of which are carrying out their own testing on Flavocide and Qcide under MTAs. These companies work in crop protection, grain storage, public health and consumer products.

Company shares are trading flat for 19.5 cents each at 12:56 pm AEST.

BGT by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…